ABBISKO-B (02256): Subsidiary ABBISKO Presents Long-Term Efficacy and Safety Data of Pimicotinib Phase III MANEUVER Study at CTOS 2025 Annual Meeting

Stock News11-17

ABBISKO-B (02256) announced that its subsidiary, Shanghai ABBISKO Biopharmaceutical Co., Ltd. (ABBISKO), presented long-term efficacy, safety, and patient-reported outcome data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for tenosynovial giant cell tumor (TGCT) patients at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting in a poster format.

The long-term analysis demonstrated that continued treatment with pimicotinib provided sustained improvement in tumor response and further enhancements in patient-reported outcomes (including pain and function) for TGCT patients, while maintaining an acceptable safety profile. These findings reinforce the long-term therapeutic potential of pimicotinib for eligible patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment